Phase I/II ECHO-202/KEYNOTE-037: Safety of Epacadostat + Pembrolizumab in Solid Tumors

June 2-6, 2017; Chicago, Illinois
In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.
Format: Microsoft PowerPoint (.ppt)
File Size: 443 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Phase I data on mesothelin-targeted CAR T-cell therapy with or without pembrolizumab in malignant pleural cancers, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 24, 2021

From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

Clinical Care Options (CCO) commentary in which Dr. Daniel Pollyea provides his strategies for treating patients with myelodysplastic syndrome (MDS)

Daniel Pollyea, MD, MS Released: September 24, 2021

DESTINY-Breast03 trial: trastuzumab deruxtecan showed clinically meaningful PFS benefit compared with trastuzumab emtansine in previously treated HER2+ metastatic breast cancer; ESMO 2021 coverage from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue